When a drug becomes as culturally prominent as semaglutide has, two things reliably follow. First, a wave of misinformation — both from people who distrust it and from people trying to sell alternatives to it. Second, a market of lower-cost versions that may or may not be what they claim. Both require an honest accounting.
I want to address both in this post with precision, because the stakes are real. Counterfeit and improperly compounded GLP-1 medications have caused serious harm. And some of the most widely circulated myths about these drugs lead patients to make worse decisions — either avoiding a medication that could genuinely help them, or pursuing versions of it that don't work or aren't safe.
Understanding Compounded Medications: What They Are and Why They Exist
Pharmaceutical compounding is a legitimate, long-standing practice in medicine. A compounding pharmacy produces custom medications — mixing ingredients to meet a patient's specific needs — when an FDA-approved version doesn't exist in the right dose, formulation, or because the patient has an allergy to an excipient in the commercial product.
Compounding is also permitted when a drug is on the FDA's official shortage list. For most of 2022–2024, semaglutide and tirzepatide were on that list because demand dramatically outpaced supply. During shortage periods, FDA regulations allowed compounding pharmacies to produce versions of the active drug to meet patient need. Many patients accessed treatment this way when they couldn't get the branded version.
The FDA has since removed semaglutide and tirzepatide from the shortage list, which changes the legal landscape significantly.
As of early 2025, the FDA has removed both semaglutide and tirzepatide from the official shortage list. This means that compounding pharmacies are no longer legally permitted to produce these drugs for general dispensing solely on the basis of shortage. Some legitimate compounding remains permissible for individual patients with specific clinical needs (allergies to excipients, specific dose requirements, etc.) when prescribed by a licensed physician. However, the large-scale commercial compounding operations that proliferated during the shortage period are now operating outside FDA regulations. If you are receiving compounded semaglutide or tirzepatide, your physician should be able to articulate the specific medical justification for the compounded product rather than the branded version.
What's Actually in Compounded GLP-1 Preparations — and Why It Matters
This is the part where I need to be very specific, because the terminology here is consequential.
Semaglutide salt vs. semaglutide base
The FDA-approved products — Ozempic, Wegovy, and Rybelsus — contain semaglutide in its free base form. Many compounding pharmacies used semaglutide sodium or semaglutide acetate — salt forms of the molecule — because these were available as research chemicals. The FDA has explicitly stated that compounded products using semaglutide salts are not equivalent to the approved product. The bioavailability, potency, and safety of the salt forms have not been established in the clinical trial data that established semaglutide's efficacy and safety. They may work similarly, or they may not. We don't know.
Tirzepatide compounding
The tirzepatide situation is more straightforward and more concerning: the active peptide in Mounjaro and Zepbound is a proprietary dual agonist molecule that is not available as a bulk active pharmaceutical ingredient through legitimate supply chains. Compounding pharmacies claiming to offer tirzepatide are sourcing from suppliers whose product quality, purity, and identity cannot be reliably verified. Independent testing of products marketed as compounded tirzepatide has found highly variable concentrations, unlabeled additives, and in some cases, the wrong compound entirely.
Products marketed as "compounded tirzepatide" from online pharmacies without a physician's prescription and documented individual medical justification represent a serious safety risk. Several adverse events — including severe hypoglycemia, dosing errors from incorrect concentration labeling, and allergic reactions to unlabeled excipients — have been reported to the FDA. The FDA has issued multiple warnings about these products. If you are currently using a compounded product and have not had this conversation with a physician, please do so before continuing.
How to Evaluate Whether a Pharmacy Is Legitimate
Legitimate compounding pharmacies exist and serve important functions. Here's how to evaluate one:
Evaluating a Compounding Pharmacy — What to Look For
Common Myths — and What the Evidence Actually Shows
"GLP-1 medications are just appetite suppressants. They're no different from diet pills."
This conflates a mechanism with an outcome. GLP-1 receptor agonists reduce appetite as one of their effects — but they do so by mimicking a gut hormone that acts on the brain's satiety center and reward circuitry, not by stimulating the central nervous system the way older stimulant-based appetite suppressants (phentermine, amphetamine derivatives) did. The broader category of effects — cardiovascular event reduction, kidney protection, liver disease improvement, potentially reduced dementia risk — cannot be explained by appetite suppression alone. These drugs are acting on GLP-1 receptors throughout the body. That's not what a diet pill does.
"You'll gain all the weight back when you stop, so what's the point?"
It's true that most patients regain significant weight after stopping GLP-1 medications — the trial data is clear on this (see Post 3). But this framing applies with equal force to blood pressure medication, cholesterol medication, and diabetes medication. Stop those and the conditions they were treating return. The relevant question is not "will stopping cause recurrence?" — the answer is yes — but rather "does treating the disease with this medication reduce harm while you're on it, and is indefinite treatment feasible?" The answer to both is yes for most patients. For patients who cannot afford indefinite treatment, the weight loss achieved during a course of GLP-1 therapy still produces meaningful, durable cardiometabolic benefits even if weight is regained over time. And habits built during treatment — exercise, dietary patterns — can partially attenuate regain.
"These medications cause muscle wasting that leaves you worse off than before."
GLP-1-mediated weight loss does include a higher-than-average proportion of lean mass loss — roughly 25–40% of total weight lost, compared to 15–25% with lifestyle-based programs. This is a real concern, not a myth. But the functional consequences are more nuanced than the headline number suggests. Current evidence does not demonstrate that GLP-1-associated muscle loss causes functional decline in most patients. Short-to-mid-term trials have generally shown preserved muscle strength despite reductions in muscle mass — and GLP-1 medications may actually improve muscle quality by reducing intramuscular fat infiltration even as absolute muscle volume decreases. The SURPASS-3 substudy found tirzepatide produced significant improvements in muscle composition with marked reductions in muscle fat infiltration across all doses, alongside only modest reductions in muscle volume proportional to overall weight loss.
The picture is genuinely different for vulnerable populations, however. A 24-month retrospective study in older adults with type 2 diabetes found semaglutide was associated with declining grip strength and significantly reduced gait speed at higher doses. Separately, there is a concerning and consistent finding across clinical studies that cardiorespiratory fitness does not improve with GLP-1 therapy despite significant weight loss — and the long-term implications of that for cardiovascular health are not yet known. The concern about muscle loss is not a myth to dismiss. It's a real risk requiring active mitigation — specifically resistance training and adequate protein — as I discuss in Post 5.
"Adding B12, glycine, or other compounds to your GLP-1 injection enhances results."
Many compounding pharmacies market GLP-1 preparations with added ingredients — B12 and glycine being the most common — often framed as enhancing efficacy, improving energy, or reducing side effects. The evidence for these additions is thin. Vitamin B12 has no established benefit for weight loss, and there is no clinical trial evidence supporting its addition to GLP-1 formulations. Glycine is somewhat more interesting: there is preliminary evidence suggesting a modest benefit for lean mass preservation during caloric restriction, but the data is early and far from conclusive. Neither addition has been studied in combination with GLP-1 medications in rigorous trials. My view is that these add-ins are primarily a marketing feature — a way to differentiate compounded products — rather than a clinically meaningful enhancement. If you are B12 deficient, that's worth treating on its own merits. But it's not a reason to choose a compounded formulation over a clinically validated one.
"GLP-1s cause depression and suicidal thoughts."
A 2025 JAMA Psychiatry meta-analysis of more than 87,000 randomized trial participants found no statistically significant increase in serious psychiatric adverse events with GLP-1 receptor agonists compared to placebo. The pharmacovigilance signal that generated this concern appears to have been a confounding artifact — GLP-1 medications were disproportionately prescribed to patients with depression and anxiety who were suffering from obesity-related distress. When controlled trials compare randomized groups, the signal disappears. Many patients, in fact, report meaningful improvements in mood, anxiety, and quality of life as they lose weight and reduce systemic inflammation.
"Compounded versions are the same drug — just cheaper."
The active peptide sequence may be the same in some legitimate compounded formulations. But pharmaceutical identity is more than the peptide sequence — it includes purity, sterility, correct concentration, formulation excipients, storage requirements, and manufacturing standards. The clinical trials that established GLP-1 safety and efficacy used the branded formulations, manufactured under strict Good Manufacturing Practices. Compounded products from unaccredited pharmacies have no such standards. Independent testing of products sold as compounded semaglutide has found highly variable concentrations — some dramatically underdosed, some significantly overdosed. For patients using a legitimate 503B outsourcing facility with a physician's prescription and documented medical rationale, the risk profile is meaningfully different from ordering a vial from an online pharmacy. The latter is not the same drug cheaper. It is a different product entirely.
"GLP-1 medications are for diabetics — they're not appropriate for people who just want to lose weight."
Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) are FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — regardless of diabetes status. The SELECT trial that demonstrated cardiovascular benefit enrolled exclusively people without diabetes. The SURMOUNT trials enrolled people without diabetes. The premise that these are "diabetic medications" reflects their origin, not their current approved indications or evidence base. Obesity is itself a chronic disease that causes cardiovascular disease, kidney disease, liver disease, joint disease, and cancer. Treating it pharmacologically is appropriate medicine, not a cosmetic shortcut.
The Elephant in the Room: Cost and Access
I want to address something directly that most physician-authored content on this topic either glosses over or avoids entirely: these medications are extraordinarily inexpensive to manufacture, and the prices Americans pay for them bear almost no relationship to the cost of making them.
A 2024 study published in JAMA Network Open by researchers at Yale University, King's College Hospital in London, and Doctors Without Borders calculated the true production cost of semaglutide by adding up every component — the active drug, other chemical ingredients, the injectable pen, packaging, manufacturing, and a reasonable profit margin. Their conclusion: a month's supply of semaglutide could be profitably produced for between 89 cents and $4.73. The active drug itself accounts for roughly 29 cents of that. Remarkably, the disposable pen used to inject it costs more to manufacture than the medicine inside it. A separate 2026 analysis from the University of Liverpool estimated generic injectable semaglutide could cost $28 to $140 per year once patents expire and generic competition enters the market.
The US list price for Ozempic is approximately $968 per month; Wegovy runs approximately $1,349 per month. Novo Nordisk has announced plans to reduce these prices to $675 in 2027. For comparison: patients in Germany pay roughly $59 per month for Ozempic; in Canada approximately $155 per month; in Japan around $100 per month; and across much of Europe between $130 and $200 per month. The manufacturing cost represents under 1% of the current US price. This is not a criticism of pharmaceutical R&D investment — bringing a drug to market is genuinely expensive, and the clinical trial programs that established these medications' safety and efficacy were enormous undertakings. But those development costs were largely recouped long ago. The current US pricing is a function of market structure, not manufacturing economics.
I want to be transparent about my own practice here, because I think patients deserve to understand how physicians who care about this issue actually navigate it. I prescribe compounded GLP-1 medications. I work with a pharmacy I have personally vetted, that has a good safety profile, and that has produced good results for my patients. I do this because I have patients with diabetes who cannot afford $700 a month for Ozempic, and patients who desperately want to lose weight to improve their health and their lives who cannot afford $500 for Zepbound. Compounding allows me to help those patients access the benefits of these medications now, rather than waiting for a pricing landscape that may not change for years.
To be clear about my clinical choices: if my patients can access FDA-approved medications for the same cost or less than a compounded version — through insurance, manufacturer savings programs, or other pathways — I always recommend and prescribe the approved product. FDA-approved is better when it's accessible. But "better" has to be weighed against "unavailable," and for many of my patients, the compounded version is the only version.
My hope is that as newer, more potent medications reach the market — and as patents expire and generic competition enters — these excellent medications will become cheaper and cheaper until everyone who would benefit from them can afford them. The University of Liverpool analysis suggests generic semaglutide could ultimately cost patients as little as $15 per month in competitive markets. That future is achievable. We are just not there yet.
Compounded GLP-1 medications occupy a spectrum from entirely reasonable to genuinely dangerous, depending on the source, the oversight, and the clinical context. The economic forces driving patients toward compounding are real, legitimate, and not going away until pricing comes down. My recommendation: if you choose compounding, choose wisely. PCAB-accredited and 503B-registered pharmacies represent the gold standard, but they are genuinely hard to find — not every patient will have access to one. At a minimum, use a licensed 503A compounding pharmacy that your physician has vetted, that provides independent lab validation of purity and concentration, and that your physician is actively monitoring you through. Do not order from an online pharmacy without clinical oversight. The quality of your source is not a technicality — it is the difference between a product that may work and one that may harm you. The goal is access to a medication that can genuinely change your health. How you get there should be as safe as possible.
Sources
- FDA Drug Shortages Database. Semaglutide and tirzepatide shortage status. 2024–2025. fda.gov
- FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. FDA Safety Communication. 2023.
- FDA Orange Book. GLP-1 receptor agonist approved products. 2026.
- Pierret ACS, et al. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023.
- Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity. Am J Clin Nutr. 2025.
- Berg S, et al. Discontinuing GLP-1 Receptor Agonists and Body Habitus. Obesity Reviews. 2025.
- Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards. pcab.pharmacy
- Barber MJ, et al. Estimated Sustainable Cost-Based Prices for Diabetes Medicines. JAMA Netw Open. 2024.
- Hill A, et al. Generic semaglutide manufacturing cost analysis. University of Liverpool preprint. 2026.
- Nauck MA, et al. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications. Lancet. 2026.
- Gonzalez-Rellan MJ, Drucker DJ. New Molecules and Indications for GLP-1 Medicines. JAMA. 2025.
- Prokopidis K. GLP-1 Receptor Agonists and Muscle Strength Changes in Older Adults. Br J Pharmacol. 2026.
- Ren Q, et al. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults With Type 2 Diabetes. Drug Des Devel Ther. 2025.
- Liu Z, et al. Incretin Receptor Agonism, Fat-Free Mass, and Cardiorespiratory Fitness: A Narrative Review. J Clin Endocrinol Metab. 2025.
- Neeland IJ, et al. Changes in Lean Body Mass With GLP-1-Based Therapies and Mitigation Strategies. Diabetes Obes Metab. 2024.